Company intelligence / Profile preview
Appili Therapeutics
- Ownership
- Public · APLI
- Development stage
- Phase 3
Overview
Appili has commercialized LIKMEZ™, the first FDA-approved ready-made liquid suspension of metronidazole. Its lead vaccine candidate, ATI‑1701, demonstrated full protection against lethal tularemia in preclinical studies and has secured significant U.S. government funding. The topical antiparasitic program ATI‑1801 has completed successful Phase III trials and received Orphan Drug Designation from the FDA.
- Therapeutic areas
- Infectious Diseases
- Modalities
- Small molecules (e.g., metronidazole liquid formulation)Vaccines (e.g., ATI-1701 for tularemia)Topical antiparasitics (e.g., ATI-1801 for leishmaniasis)
- Industry
- Biotech
Drug pipeline
7 assets6 more assets in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on Appili Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Appili Therapeutics.